Market revenue in 2023 | USD 1,323.4 million |
Market revenue in 2030 | USD 4,753.6 million |
Growth rate | 20% (CAGR from 2023 to 2030) |
Largest segment | Adeno-associated virus (aav) |
Fastest growing segment | Adeno-associated virus (AAV) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector and plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Adeno-associated virus (aav) was the largest segment with a revenue share of 20.15% in 2023. Horizon Databook has segmented the Europe viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest share in the market in 2022, following North America, and is estimated to grow at a CAGR of xx% over the forecast period. The market growth can be attributed to an increase in research funding and the presence of local key market players in this region.
The number of biopharmaceutical companies is growing in Europe owing to increasing investments. For instance, in February 2022, the UK pledged around USD 192 million to the Coalition for Epidemic Preparedness Innovations for boosting vaccine development.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe viral vector and plasmid dna manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe viral vector and plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account